Q-omics provides the consensus-scored CSNK1G3 profile across patient tissues and cancer cell-line models. CSNK1G3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSNK1G3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CSNK1G3 RNA expression shows 20,302 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where CSNK1G3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK1G3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK1G3 survival associations across molecular data types. CSNK1G3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK1G3 RNA expression–survival associations across cancer types. High CSNK1G3 expression shows unfavorable associations in KIRP, KICH, HNSC, OV and UVM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSNK1G3 RNA expression.
This table summarizes CSNK1G3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CSNK1G3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK1G3 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, STAD, ESCA and LIHC. The HNSC box plot shows higher CSNK1G3 RNA expression in tumor versus normal tissue (log2 FC = +0.468, t-test p < 0.001).
This table shows molecular features associated with CSNK1G3 in patient tissues and cancer cell lines. In patient samples, CSNK1G3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSNK1G3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
